e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:04/Issue:04/April-2022 Impact Factor- 6.752 www.irjmets.com

CROHN'S DISEASE: BRIEF OUTLINE

Ajay Sabale*1, Payal Patil*2, Mrunalini Unecha*3, Prof. Santosh Waghmare*4, Prof. Andhle A.K*5, Dr. Hemant Kamble*6

*1,2Student, Department Of Pharmacology, Loknete Shri Dadapatil Pharate College Of Pharmacy, Mandavgan Pharate, Shirur, Pune, Maharashtra, India.

*3Student, Department Of Pharmaceutics, Loknete Shri Dadapatil Pharate College Of Pharmacy, Mandavgan Pharate, Shirur, Pune, Maharashtra, India.

*4,5Professor, Department Of Pharmacy, Loknete Shri Dadapatil Pharate College Of Pharmacy, Mandavgan Pharate, Shirur, Pune, Maharashtra, India.

*6Principle, Department Of Pharmacy, Loknete Shri Dadapatil Pharate College Of Pharmacy, Mandavgan Pharate, Shirur, Pune, Maharashtra, India.

ABSTRACT

Foundation: Treatment of Crohn's infection (CD) patients is intricate as treatment decisions rely upon an assortment of elements, like area and seriousness of aggravation, sickness conduct (fiery, organizing or entering) yet additionally comorbidities, extra-digestive indications, the patient's age, and past treatments. Therefore, the decision of treatment ought to be customized to the singular patient. The frequency of Crohn's sickness has consistently expanded throughout recent many years. The conclusion and treatment of patients with Crohn's sickness has developed since the last practice rule was distributed. These rules address the authority practice suggestions of the American College of Gastroenterology and were created under the sponsorship of the Practice Parameters Committee for the administration of grown-up patients with Crohn's illness. Late information on immunomodulatory and biologic treatments in the treatment of fiery inside illnesses (IBD) has laid out new objectives in the enlistment and upkeep of reduction of these infections. This article surveys momentum information on epidemiological and clinical angles, a methodology in the assessment of the patient and a concise audit on treatment of Crohn's illness. While full ileocolonoscopy with biopsies stays the pillar for determination, other less intrusive imaging modalities are by and large effectively thought to be in the workup, as well as the utilization of serological markers. The board should fuse dietary and way of life alterations where vital, the utilization of prescriptions in acceptance and reduction of infection, and thought of careful mediation where clinical treatment has fizzled.

I. INTRODUCTION

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with backsliding and dispatching indications that might prompt inside harm and incapacity after some time. Along these lines, early analysis and satisfactory treatment ought to be accomplished. Any piece of the gastrointestinal plot can be impacted by CD, the most widely recognized being the terminal ileum and the colon[1]. Crohn's infection has been expanding in frequency and predominance around the world. Simultaneously, the quantity of restorative choices is quickly expanding. The motivation behind this rule is to survey Crohn's infection clinical highlights and normal history, diagnostics, and helpful mediations. Clinical indications are various and by far most are optional to the fiery cycle that harms digestive mucosa and more profound layers, causing loss of surface ingestion, divider thickening, block or fistulation. Differential analysis incorporates gastrointestinal tuberculosis and malignancies. In situations where there is a solid doubt, extraordinary picture procedures, and serum and waste biomarkers should be performed. Presently, there is no authoritative treatment for CD; be that as it may, the advancement of natural treatments has permitted the methodology of new helpful targets, which enhance manifestations, defer movement of confusions and work on personal satisfaction. This audit centers around momentum information on Crohn's Disease[2].

Causes:

Genetics:

Familial aggregation has been known for over 70 years and huge concordance studies in twins in northern Europe were early signs of a hereditary part in Crohn's sickness. This information has been affirmed in

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:04/Issue:04/April-2022 Impact Factor- 6.752 www.irjmets.com

different nations. A German cross-country study[3] showed that 35% of monozygotic sets, however just 3% of dizygotic sets, were concordant for the problem. In 70% of discordant monozygotic sets the principal conceived had IBD[3]. Substantial phenotypic (area, conduct, and age at determination) concordance exists, both at diagnosis and longitudinally, in monozygotic twins[4]. Familial aggregations are confirmed[5]. Moreover, pervasiveness in Ashkenazi Jews is higher than in some other ethnic gathering and Jewish plummet is an autonomous danger factor for the issue. Hereditary expectation i.e., prior illness beginning in the off spring of guardians with the problem has been confirmed[6]. Genome wide affiliation review and electronic (in silico) meta-investigations have distinguished and affirmed susceptibility loci for Crohn's infection on 17 chromosomes up to this point[7]. The ID of vulnerability loci has upgraded how we might interpret the reasons for the issue by giving significant insights about pivotal and upset pathways of the gastrointestinal resistant framework. Enthusiasm for the job of the natural safe reaction in Crohn's illness came about because of the revelation.

Environmental factors:

Around the world, north-south, east-west, and metropolitan provincial inclinations for occurrence rates and predominance of Crohn's infection have been recognized[8]. However, an efficient geographic investigation[9], new examinations from southern half of the globe nations detailing rates that are similarly as those in the northern side of the equator[10] and reports of an expanded frequency in rustic, periurban regions[11] contend against an autonomous geographic part. Aside from hereditary qualities, a few elective clarifications, generally connected with way of life, are conceivable. The significance of climate is proposed by expanding frequency rates in already less impacted ethnic gatherings like Asians and Hispanics[12] and in foreigners from low-rate regions moving to regions with a generally high occurrence[13]. Industrialization has significantly impacted individuals' lives with an attention on vocation and advanced education[14], more advance life[15], less ladies breastfeeding[16], more modest families with less jam-packed day to day environments, worked on homegrown cleanliness and sterilization[17], accessibility and nature of (hot) faucet water[18], reception of a stationary way of life[19], openness to air contamination[20], utilization of a western eating routine stacked with comfort food sources[21] (frequently containing over the top measures of sugar and polyunsaturated fats), and expanded tobacco use. Although these elements have been implicated in Crohn's illness, dynamic[22] and detached[23] (even in adolescence) smoking are best contemplated. Early tobacco use altogether expands the danger of fostering the problem[24]. Robotically, obviously neither nicotine nor carbon monoxide are the reason.

Microbiota:

Metagenomic research recommends that up to four significant bacterial phyla (Bacteroidetes, Firmicutes, Actinobacteria, and Proteobacteria) comprising of thousands of generally anaerobic species colonize the human stomach with a precarious, stomach-acid driven, proximal-distal gradient. Species variety in the stomach ordinarily additionally shifts as indicated by transient[25], individual[26,27], dietary[28], and medication actuated[29] variables. In any case, solid digestive microbiota variety is by and large delineated and not consistent[30]. Similar studies showed grouping[31] and diminished variety particularly inside the Firmicutes and Bacteroidetes phyla in patients with Crohn's sickness[32-34]. A decrease of Faecalibacterium prausnitzii (a Firmicute), was related with an expanded danger of postoperative repeat of ileal Crohn's sickness and its test compensation had calming impacts[35]. Crohn's infection isn't brought about by lessened commensal variety alone, yet requires a vulnerable genotype-as affirmed by research in mice with human-applicable defenselessness changes.

Pathophysiology:

It is realized that there are hereditary variables (quality CARD 25/NOD2 transformations and polymorphisms of TLR) and natural elements (smoking, drugs, societal position, stress, microorganisms, diet, appendectomy and digestive porousness) that partake in the physiopathology of this infection. The most acknowledged hypothesis recommends that digestive irritation is created by a strange reaction from the lymphocytes T against intestinal bacterial verdure in hereditary powerless individuals[36].

In CD overexpression of cost like receptors (TLR) could instigate a change in the acknowledgment and segregation of their own bacterial verdure, bringing about actuation of cytokines like NF-B. Such adjustment of the inborn insusceptibility prompts an uncontrolled actuation of lymphocytes T assistant, particularly Th1 reaction, and the arrival of pro inflammatory middle people like TNF-, finishing in tissue obliteration.

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:04/Issue:04/April-2022 Impact Factor- 6.752 www.irjmets.com

At long last, there is an overstated creation of antibodies (ASCA), and both administrative lymphocytes T and lymphocyte apoptosis are changed, along these lines restricting mitigating instruments[36,37].

Diagnostic instruments:

Endoscopy:

The highest quality level for all patients with Crohn's illness is a full ileocolonoscopy with biopsies. Chromoendoscopy with methylene blue color splash designated biopsies brings about superior detection of dysplasia contrasted and conventional arbitrary and sequential biopsy strategies[38]. Although advanced choices, for example, restricted band imaging are less tedious, they can't be suggested as a standard method in view of expanded paces of missed dysplasia[39]. Capsule endoscopy may be more delicate compared and enterography or enteroclysis joined with CT (CTE) and MRI (MRE) in patients without clinical suspicion of stenosis[40].

CT and MRI enterography or enteroclysis:

Enteroclysis is recognized from enterography by the need to apply luminal contrast through an intestinal tube. CTE offers the most elevated spatial resolution and has supplanted little gut fluoroscopy in driving communities. It is exceptionally delicate, can show aggravation missed by different strategies, can recognize complications like impediment, fistulas, and abscesses, and could even be detailed. Its significant drawback is high radiation openness, although complex numerical calculations of picture procurement and handling can diminish it. MRE is a non- radiating, non-iodine-contrast based option in contrast to CTE. With proper conventions it can give films to evaluate motility and definite imaging of the inside divider down to mucosal level. It is the favored decision for continued imaging, long haul follow-up and work-up of perianal fistula and abscess complications (figure 1)[41].



Fig 1: Stenosis in Crohn's disease

(A) MR enterography of Crohn's disease restricted to the terminal ileum (Montreal category L1) with inflammatory stenosis.

(B) Ultrasound image of an intestinal stenosis in Crohn's disease.

Ultrasound (sonography):

Local and (gas or shell microbubble) contrast-upgraded stomach ultrasound (figure 1) is a promptly accessible, painless imaging procedure with a general awareness and specificity that are similarly as with MRI and CT[41]. Imminent examinations have shown utility for the initial diagnosis, appraisal of sickness action, recognition of fistulas, stenosis and abscesses, and critical connection with histopathology, research facility discoveries, approved infection movement files, and endoscopy. Trans rectal furthermore endoscopic ultrasound can aid perianal intricacies (figure 1).

Biomarkers:

X-ray based imaging methods are a significant wellspring of openness to ionizing radiation and can bring about high combined powerful dosages. Patients with Crohn's infection had a 2.5 times higher absolute compelling portion than did those with ulcerative colitis in one study[42]. Efforts to follow-up patients with the un-obtrusive

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:04/Issue:04/April-2022 Impact Factor- 6.752 www.irjmets.com

methodology and put together choices with respect to objective, cost-effective variables drive the revelation, improvement, and evaluation of biomarkers[43]. The best contemplated follow-up biomarkers are C- reactive protein and the fecal granulocyte proteins lactoferrin and calprotectin. A few examinations have affirmed great relationship with other lab tests, endoscopic and clinical sickness action files, and conceivable predictive potential.

TREATMENT OF CROHN'S DISEASE:

Treatment of CD ought to be directed by seriousness, behavior, sickness area, complications, therapy refractoriness and reliance to steroids. CD treatment is differentiated into drugs initiating reduction and for maintenance of remission[44].

First line drugs in the treatment for Crohn's disease:

5-Aminosalicylates-

This sort of medications is the exemplary first line treatment, there are oral and rectal arrangements. A portion of these medications are Sulfalazine, Mesala-zine, Olsalazine and Balsalazide. Rectal introductions are just helpful when CD is dynamic in colon and rectum. Primarily utilized in reactivation and for enlistment to reduction, when movement of the illness is gentle to direct[45]. For CD the favored aminosalicylate is Mesalazine 4-6 g/day, for its movement in small digestive tract, additionally it is the best endured. Most normal results of these medications (10-40%) are migraine, sickness, epigastric agony, looseness of the bowels, Oligospermia (Sulfasalazine). Seldom Steven's Johnson condition, pancreatitis, agranulocitosis and alveolitis. It is prescribed to begin treatment with Folinic corrosive, to keep away from weakness and different pathologies related with its deficiency[46].

Steroids-

This are the most utilized when there is serious action, absence of reaction to treatment with 5-ASA or when a fast incendiary reaction is required. Various sorts of steroids might be use in a flare, but steroids ought not be utilized as an upkeep treatment in long haul, on account of fundamental aftereffects. For acceptance of abatement, Prednisolone 40 mg/day, in a decrease routine, accomplishes fast clinical reaction. The proof shows higher dosages don't give more noteworthy advantage and do raise the quantity of unfriendly responses. Drug suspension should be done through a decrease conspire, with an estimated length of about two months, as sudden decreases are related to more reactivations. Then again, dosages < 15 mg/day have been pointless for acceptance to reduction.

Budesonide is an intraluminal steroid, with minimal fundamental assimilation, and it is by all accounts as valuable as prednisolone exceptionally in low or moderate activity.42 Administration course of steroids relies upon area what's more seriousness of the sickness.

a) Intravenose - Metilprednisolone 60 mg/day, hydrocortisone 400 mg/day in extreme activity or with contraindication for oral use.

b) Oral - prednisolone, prednisone and budesonide, in moderate to extreme action.

here are number of patients that will neglect to steroid treatment; these are known as unmanageable and the individuals who don't accomplish remission without the utilization of steroids known as steroid dependent. We can involve Thiopurines as Azathioprine or 6-mercaptopurine as saving steroid.

Second line drug therapy in Crohn's disease:

Immunomodulators-

A normalized decrease plot assists with recognizing refractory patients, and who might require an adjuvant treatment. Opposition and absence of reaction to steroid treatment should cause us to think about a medical procedure. Some second line clinical treatments incorporate an inmunosupressor appropriate for the seriousness and sort of disease.

Thiopurines-

The Azathioprine in a 2-2.5 mg/kg/day portion or 6-mercaptopurine in a 0.75 to 1.5 mg/kg day portion, may be valuable for actuating remission or as a support treatment in patients that fall flat or are intolerant to 5-ASA and that require repetitive steroid cycles. In spite of the fact that its impact is deferred, between 4-6 weeks, and its utilization alone isn't suggested, it is helpful as a saving steroid specialist and in the treatment of CD with

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:04/Issue:04/April-2022 Impact Factor- 6.752 www.irjmets.com

fistulas of any kind. It is vital to bar different inconveniences as impediment or abscesses. The more normal aftereffects are hypersensitive responses, leucopenia, pancreatitis, bone marrow and liver toxicity[47].

Methotrexate-

This medication has shown its utility in the acceptance and upkeep treatment of patients with CD in those patients intolerant or impervious to Thiopurines treatment. Methotrexate ought to be controlled with 5 mg of folinic corrosive following three days of organization, to lessen its adverse impacts related with the restraint of the dihydrofolate reductase. The most widely recognized unfavorable impacts of this medication are gastrointestinal manifestations (sickness, regurgitation, looseness of the bowels or stomatitis), hepatotoxicity, neumonitis and contamination related with crafty specialists. Methotrexate is additionally a teratogenic specialist and is contraindicated during pregnancy or in ladies on regenerative age without a viable anticonception treatment. Pregnancy should be arranged as long as a half year after the medication suspension. It is additionally not suggested during breast feeding and ethanol utilization should be also avoided[48-50].

Calcineurin inhibitors-

Cyclosporine and Tacrolimus are instances of this kind of medications. The two of them smother humoral and cell resistance, avoiding the clonal development of T cells. These medications are valuable in the treatment of UC, in spite of the fact that they have not demonstrated to be helpful in the treatment of CD.

Tumor necrosis factor alpha inhibitors-

Practically all current guidelines suggest Anti TNF as second line treatment for IBD the utilization of these medications. Against TNF utilized for treatment of CD are adalimumab, infliximab and certolizumab pegol[51-53]. There is some new data that propose that these medications might be utilized as first-line treatments in CD of late conclusion, particularly infliximab and azathioprine, this methodology is known as "hierarchical", treatment and the proof shows speedy abatement in patients with this treatment mode.

Anti-integrin monoclonal antibodies-

Presently there are three helpful medications for patients with CD, natalizumab, vedolizumab and ustekinumab. Current guidelines still not think about the utilization of this medications for the treatment of IBD, yet there is late proof that has shown its utility[56].

II. CONCLUSION

We have done a broad review of the accessible clinical literature in regards to CD. There are as yet specific gaps in the evidence in regards to the analysis and the executives of CD. In spite of the fact that it is an interesting multifactorial sickness, the rate and predominance are expanding. Every persistent should be evaluated exclusively to figure out which investigation is generally suitable, thinking about age, associated area with infection, illness seriousness and probability of repeat. Inconveniences can be extreme; brief determination and early treatment are crucial for yield a superior forecast. Various demonstrative procedures, be it serological markers or imaging modalities, have helped both finding and checking of CD. Treatment is expected to initiate reduction and to keep up with the sickness idle. Nonetheless, progress and advancement of novel treatment specialists is focused on for further developing visualization and personal satisfaction.

III. REFERENCE

[1] Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006 Jun; 55(6): 749–53.

[2] Guyatt G, Oxman A, Vist G et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924 – 6.

[3] Spehlmann ME, Begun AZ, Burghardt J, Lepage P, Raedler A, Schreiber S. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis 2008; 14: 968–76.

[4] Ng SC, Woodrow S, Patel N, Subhani J, Harbord M. Role of genetic and environmental factors in British twins with inflamatory bowel disease. Inflamm Bowel Dis 2012; 18: 725–36.

[5] Bengtson MB, Solberg C, Aamodt G, et al, and the IBSEN study group. Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years. J Crohn's Colitis 2009; 3: 92–99.

[6] Bengtson MB, Solberg C, Aamodt G, et al, and the Ibsen Study Group. Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease. Inflamm Bowel Dis 2009; 15: 1867–74.

[7] Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118.

[8] Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504–17.

[9] Aamodt G, Jahnsen J, Bengtson MB, Moum B, Vatn MH, and the IBSEN Study Group. Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990–1993. Infl amm Bowel Dis 2008; 14: 984–91.

[10] Abakar-Mahamat A, Filippi J, Pradier C, Dozol A, Hébuterne X. Incidence of inflammatory bowel disease in Corsica from 2002 to 2003. Gastroenterol Clin Biol 2007; 31: 1098–103.

[11] Declercq C, Gower-Rousseau C, Vernier-Massouille G, et al. Mapping of inflammatory bowel disease in northern France: spatial variations and relation to affluence. Inflamm Bowel Dis 2010; 16: 807–12.

[12] Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol 2009; 104: 2100–09.

[13] Joossens M, Simoens M, Vermeire S, Bossuyt X, Geboes K, Rutgeerts P. Contribution of genetic and environmental factors in the pathogenesis of Crohn's disease in a large family with multiple cases. Inflamm Bowel Dis 2007; 13: 580–84.

[14] Aamodt G, Jahnsen J, Bengtson MB, Moum B, Vatn MH, and the IBSEN Study Group. Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990–1993. Inflamm Bowel Dis 2008; 14: 984–91.

[15] Lerebours E, Gower-Rousseau C, Merle V, et al. Stressful life events as a risk factor for inflammatory bowel disease onset: A population-based case-control study. Am J Gastroenterol 2007; 102: 122–31.

[16] Barclay AR, Russell RK, Wilson ML, Gilmour WH, Satsangi J, Wilson DC. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr 2009; 155: 421–26.

[17] Gent AE, Hellier MD, Grace RH, Swarbrick ET, Coggon D. Inflammatory bowel disease and domestic hygiene in infancy. Lancet 1994; 343: 766–67.

[18] Aamodt G, Bukholm G, Jahnsen J, Moum B, Vatn MH, and the IBSEN Study Group. The association between water supply and inflammatory bowel disease based on a 1990–1993 cohort study in southeastern Norway. Am J Epidemiol 2008; 168: 1065–72.

[19] Bernstein CN, Kraut A, Blanchard JF, Rawsthorne P, Yu N, Walld R. The relationship between inflammatory bowel disease and socioeconomic variables. Am J Gastroenterol 2001; 96: 2117–25.

[20] Kaplan GG, Hubbard J, Korzenik J, et al. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol 2010; 105: 2412–19.

[21] Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 2011; 106: 563–73.

[22] Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J. Effects of light smoking consumption on the clinical course of Crohn's disease. Inflamm Bowel Dis 2009; 15: 734–41.

[23] 27 Jones DT, Osterman MT, Bewtra M, Lewis JD. Passive smoking and infl ammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008; 103: 2382–93.

[24] 28 Tuvlin JA, Raza SS, Bracamonte S, et al. Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts. Inflamm Bowel Dis 2007; 13: 573–79.

[25] Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science 2009; 326: 1694–97.

[26] Turnbaugh PJ, Quince C, Faith JJ, et al. Organismal, genetic, and transcriptional variation in the deeply sequenced gut microbiomes of identical twins. Proc Natl Acad Sci USA 2010; 107: 7503–08.

[27] Claesson MJ, Cusack S, O'Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011; 108 (suppl 1): 4586–91.

[28] Muegge BD, Kuczynski J, Knights D, et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 2011; 332: 970–74.

[29] Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011; 108 (suppl 1): 4554–61.

[30] Arumugam M, Raes J, Pelletier E, et al, and the MetaHIT Consortium. Enterotypes of the human gut microbiome. Nature 2011; 473: 174–80.

[31] Qin J, Li R, Raes J, et al, and the MetaHIT Consortium. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59–65.

[32] Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780–85.

[33] Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profi les vary with inflammatory bowel disease phenotypes. Gastroenterology 2010; 139: 1844–54, e1.

[34] Moussata D, Goetz M, Gloeckner A, et al. Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut 2011; 60: 26–33.

[35] Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731–36.

[36] Strober W, Asano N, Fuss I. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease. Immunol Rev 2014; 260(1): 249-60.

[37] Van Assche G, Dignass A, Panes J. The second European evidence- based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Journal of Crohn's and Colitis 2010; 4(1): 7-27.

[38] Ferrer I, Hinojosa del Val J. Definiciones, manifestaciones clínicasy diagnóstico de la enfermedad de Crohn. Medicine 2012; 11(5): 257-65.

[39] Marion JF, Waye JD, Present DH, et al, and the Chromoendoscopy Study Group at Mount Sinai School of Medicine. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 2008; 103: 2342–49.

[40] Pellisé M, López-Cerón M, Rodríguez de Miguel C, et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc 2011; 74: 840–48.

[41] Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol 2010; 105: 1240–48, quiz 1249.

[42] Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008; 103: 2394–400.

[43] 97 Peloquin JM, Pardi DS, Sandborn WJ, et al. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2008; 103: 2015–22.

[44] 98 Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817–26, e2.

[45] Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2013; (4): CD000545.

[46] Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-9.

[47] Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008; 103: 1783-800.

[48] Arora S, Katkov W, Cooley J. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46: 1724-9.

[49] Feagan BG, Fedorak RN, Irvine EJ, Wild G. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-32.

[50] Fraser AG. Methotrexate: first-line or second line immunomodulator? Eur J Gastroenterol Hepatol 2003; 15: 225-31.

[51] Narula N, Kainz S, Petritsch W. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti- TNF-α naïve Crohn's disease. Aliment Pharmacol Ther 2016; 44(2): 170-80.

[52] Takeshima F, Yoshikawa D, Higashi S. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. BMC Gastroenterology 2016; 16: 82.

[53] Loftus EV Jr., Colombel JF, Schreiber S. Safety of long-term treatment with certolizumab pegol in patients with Crohn's disease, based on a pooled analysis of data from clinical trials. Clin Gastroenterol Hepatol 2016. pii: S1542-3565(16)30440-2.

[54] Ungar B, Kopylov U. Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol 2016; 29: 243-8.

[55] Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther 2016: 1-14.

[56] Khanna R, Mosli MH, Feagan BG. Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What is their place? Dig Dis 2016; 34(1-2): 153-9.